IP Library Granted Patent US 10,751,400
Granted Patent B2
US 10,751,400 · App. 16/551,138 · Granted Aug 25, 2020

DNA vector and transformed tumor cell vaccines

Inventors: Michael J. P. Lawman (Temple Terrace, FL); Patricia D. Lawman (Temple Terrace, FL); Vijay Ramiya (Tampa, FL); Meghan Gentilini (St. Petersburg, FL)
Assignee: MORPHOGENESIS, INC.
A61K39/0011A61K39/092A61K45/06A61K2039/5152A61K2039/5156A61K2039/53A61K2039/54A61K2039/552A61K2039/55527A61K2039/55533A61K2039/55538A61K2039/585
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,751,400
App. No.
16/551,138
Granted
Aug 25, 2020
Kind
B2
Abstract

Customized whole cell cancer vaccines can be produced from autologous (ex vivo or in situ) or allogeneic human or veterinary patient cell lines. Cells are transformed with S. pyogenes DNA that expresses an Emm protein on the cell surface and cytosol. Treatment of cancer patients with an Emm vector vaccine induces an immunologic response to the cancer by enhancing immunogenicity of a tumor. Emm vaccines can be used in patients where the cancer is not identified due to lower tumor burden or used to treat a specific cancer and subsequently treat for a second type that may have arisen through metastasis.

Claims (10)

1. A method for preparing a membrane anchoring protein, comprising:

inserting a first DNA encoding the amino acid sequence of SEQ ID NO: 7 into the N-terminal signal region of a DNA encoding an M serotype 55 group A streptococcus protein;

inserting a second DNA encoding the amino acid sequence of SEQ ID NO: 9 into the C-terminal anchor region of the DNA encoding said protein;

wherein the encoded protein expressed from the modified DNA is a membrane anchoring protein.

2. The method of claim 1 wherein the M serotype 55 group A streptococcus protein is a gram positive bacterial cell wall protein.

3. The method of claim 2 wherein the gram positive bacterial wall protein is from a serotype of group A Streptococcus.

4. The method of claim 1 wherein the encoded protein has the amino acid sequence of SEQ ID NO: 5.

5. The method of claim 1 wherein the membrane anchoring protein anchors to a cell membrane.

6. The method of claim 5 wherein the cell membrane is a eukaryotic membrane.

7. The method of claim 5 wherein the cell membrane is a prokaryotic membrane.

Assignments (3)
SECURITY INTEREST Recorded Apr 22, 2026
From: TUHURA BIOSCIENCES, INC.; ADGERO BIOPHARMACEUTICALS HOLDINGS INC.; ADGERO BIOPHARMACEUTICALS, INC.; KINETA, LLC
To: PARKVIEW HOLDINGS ONE LLC
Reel/Frame 074439/0057 →
CHANGE OF NAME Recorded Jan 30, 2024
From: MORPHOGENESIS, INC.
To: TUHURA BIOSCIENCES, INC.
Reel/Frame 066380/0060 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 27, 2019
From: LAWMAN, MICHAEL J. P.; LAWMAN, PATRICIA D.; RAMIYA, VIJAY; GENTILINI, MEGHAN
To: MORPHOGENESIS, INC.
Reel/Frame 050175/0521 →
Continuity (5)
Division 15837965 · Dec 11, 2017
Continuation In Part 15418798 · Jan 30, 2017
Division 15110248
Provisional Application 61948980 · Mar 6, 2014
Related Publication 20200000901A1 · Jan 2, 2020